Vertex Pharmaceuticals — Q3 2012 Form 10-Q
Business context and reporting period. Unaudited results cover the quarter and nine months ended September 30, 2012. Vertex develops and commercializes medicines for serious diseases. Its marketed products were INCIVEK for hepatitis C (HCV) and KALYDECO for cystic fibrosis (CF); collaborators marketed telaprevir as INCIVO and TELAVIC outside Vertex’s direct markets. Alios BioPharma is consolidated as a variable interest entity, although Vertex’s interests in Alios’s assets and obligations are limited by their agreement.
Key financial results
| Metric | Three months ended Sept. 30, 2012 | Nine months ended Sept. 30, 2012 |
|---|---|---|
| Total revenue | $336.0 million, down 49% year over year | $1,193.0 million, up 41% |
| Net product revenue | $303.5 million, down 28% | $1,052.1 million, up 113% |
| Operating income (loss) | $(1.1) million | $79.8 million |
| Net income (loss) attributable to Vertex | $(57.5) million; $(0.27) per diluted share | $(30.9) million; $(0.15) per diluted share |
| Research and development expense | $200.2 million | $593.1 million |
| Net cash from operating activities | Not separately provided for the quarter | $227.3 million, versus $(359.9) million in 2011 |
Operating margin was approximately (0.3)% for Q3 and 6.7% year to date, based on reported operating income and revenue. Product cost was $30.7 million in Q3 and $161.1 million year to date; the latter includes a $78.0 million second-quarter write-down of excess and obsolete INCIVEK inventory.
At September 30, cash, cash equivalents and marketable securities totaled $1.30 billion, excluding Alios cash, up $329.6 million from year-end 2011. Current assets were $1.63 billion and current liabilities $406.7 million. Debt included $400 million of 3.35% convertible notes due October 2015; the balance sheet also included a $216.0 million construction financing obligation. The $100 million revolving credit facility expired in July 2012 unused.
Material changes versus the prior comparable period
- Q3 revenue fell primarily because 2011 included $200 million of Janssen milestone revenue and because INCIVEK sales declined. Q3 2012 product revenue included $254.3 million from INCIVEK and $49.2 million from KALYDECO.
- Year-to-date revenue rose as product revenue increased by $558.0 million and royalty revenue by $73.4 million, partly offset by a $285.7 million decline in collaboration revenue. The 2011 comparison included substantial Janssen milestones and other collaboration revenue.
- INCIVEK product revenue declined $165.3 million year over year in Q3; KALYDECO contributed $49.2 million. From Q2 to Q3 2012, total product revenue fell $69.8 million as lower INCIVEK sales more than offset modest KALYDECO growth. Janssen telaprevir royalties were $20.0 million in Q3, down from $28.0 million in Q2.
- Year-to-date operating costs increased 16%, reflecting higher product costs, R&D, SG&A and royalties; the comparison also benefited from the absence of the $105.8 million VX-759 impairment charge recorded in 2011. The company reported a $78.0 million INCIVEK inventory write-down in 2012.
Outlook, commentary, risks and unusual items
- Management expected INCIVEK revenue and INCIVO royalties to continue declining under competitive pressure, with KALYDECO growth partly offsetting the decreases. Management stated available funds and expected product cash flows should fund operations for at least the next 12 months; this depends on product revenue and R&D needs. No numerical revenue or earnings guidance was provided.
- Vertex planned to evaluate VX-135 in several all-oral HCV combinations, with clinical trials expected to begin from late 2012 into early 2013, subject to regulatory discussions. It ended ALS-2158 development after Phase 1 results showed insufficient antiviral activity, and also ended VX-765 development.
- In CF, Vertex was pursuing additional ivacaftor studies and preparing a pivotal VX-809/ivacaftor program, subject to regulatory discussions. It also had ongoing programs for VX-661, rheumatoid arthritis candidate VX-509 and influenza candidate VX-787. Timelines and outcomes remain uncertain.
- HCV competition and rapid development of new treatments could further reduce INCIVEK demand and prompt additional inventory write-downs. Vertex also cited clinical-development, regulatory, reimbursement, manufacturing and third-party supply risks. R&D spending was substantial and successful development was uncertain.
- The increase in the estimated fair value of contingent milestone and royalty obligations to Alios was $57.6 million in Q3 and $112.8 million year to date, reflecting VX-135 progress. This accounting item affected the allocation of reported earnings to Vertex and could increase if the program advances.
- A shareholder securities class action filed in September 2012 alleges misrepresentations or omissions in disclosures from May 7 through June 28, 2012. Vertex said it considered the suit without merit and intended to defend it; no reserve was recorded. Management noted the litigation could consume resources and that the outcome was uncertain.
- The Fan Pier buildings and related construction financing obligation increased as construction continued; lease payments were expected to begin in late 2013 or early 2014. The filing reported no material accrued contingent liabilities at September 30.
Important facts for investors to verify
- Subsequent INCIVEK and INCIVO sales, KALYDECO uptake and European reimbursement progress.
- Whether HCV competition drives further demand reductions, inventory charges or royalty declines.
- VX-135 clinical and regulatory progress, and the assumptions underlying the Alios contingent-payment valuation.
- Cash generation relative to R&D and commercialization spending, plus refinancing or repayment plans for the 2015 notes and future Fan Pier obligations.
- Developments and potential costs in the securities class action, and any changes in manufacturing or supply-chain risks.